Strong Revenue Performance#
UroGen Pharma Ltd. (URGN) has announced its Q1 2026 earnings, showcasing a revenue of $51 million, which is 14.62% higher than analysts' expectations. This impressive figure represents a 152% increase compared to the same quarter last year, primarily driven by the successful launch of its product, ZUSDURI.
Financial Highlights#
In addition to robust revenue, UroGen reported an earnings per share (EPS) of -$0.47, which is an improvement from the anticipated -$0.50. The company’s net loss per share also saw a significant reduction, down 46.1% from the previous year. As of March 31, 2026, UroGen's cash reserves, including cash equivalents and marketable securities, stood at $140.3 million, positioning the company well for future growth.
Market Reaction#
Following the earnings announcement, UroGen’s stock experienced a 5.83% increase in pre-market trading, reaching $25.22. This rise reflects positive investor sentiment and confidence in the company’s growth prospects, especially given its 52-week stock range of $3.42 to $30.
Future Outlook#
Looking ahead, UroGen anticipates continued growth, projecting total revenue of $245.05 million for FY 2026. The company is optimistic about moving towards profitability by FY 2027, supported by its strategic focus on expanding ZUSDURI’s market presence and advancing its product pipeline. CEO Liz Barrett emphasized the significance of ZUSDURI's launch, noting its strong market demand and the positive impact of UroGen's strategic investments.